Can Ivermectin Enhance Immunotherapy in Breast Cancer? Trial NCT05318469
A Complete Analysis of Clinical Trial NCT05318469
Triple-negative breast cancer (TNBC) remains one of the most aggressive and difficult-to-treat forms of breast cancer. Unlike other subtypes, TNBC lacks expression of estrogen receptors (ER), progesterone receptors (PR), and HER2. This absence eliminates many of the most effective targeted therapies, leaving patients with fewer treatment options and often poorer outcomes.
In the metastatic setting, even advanced treatments such as immune checkpoint inhibitors—like pembrolizumab—have shown limited durability in a significant proportion of patients. This has driven urgent interest in novel strategies that can enhance immunotherapy response.
One of the most closely watched approaches is clinical trial NCT05318469, which is investigating whether ivermectin, a well-known antiparasitic drug, can improve the effectiveness of immune checkpoint inhibitors in metastatic TNBC.
What Is Clinical Trial NCT05318469?
NCT05318469 is a Phase I/II clinical trial being conducted at Cedars-Sinai Medical Center in Los Angeles. The study is actively recruiting patients with metastatic triple-negative breast cancer who have previously undergone systemic treatment.
Study Overview:
- Condition: Metastatic triple-negative breast cancer (mTNBC)
- Phase: I/II
- Location: Cedars-Sinai Medical Center
-
Intervention:
- Oral ivermectin
-
Immunotherapy (balstilimab or pembrolizumab)
-
Primary Goals:
- Evaluate safety and tolerability
- Identify optimal dosing
- Assess early anti-tumor activity
This trial represents one of the first structured human investigations into ivermectin as a potential immunotherapy enhancer in solid tumors.
Why Ivermectin? The Scientific Rationale
The use of ivermectin in oncology is based on emerging preclinical evidence, not anecdotal use. Researchers have identified several biological mechanisms that suggest ivermectin may influence both tumor cells and the immune system.
Key Anti-Cancer Mechanisms (Preclinical Evidence)
1. Immune System Modulation
Ivermectin may:
- Increase T-cell infiltration into tumors
- Reduce regulatory T cells (Tregs) that suppress immune response
- Promote immune-mediated tumor cell killing
These effects could help convert “cold tumors” (immune-resistant) into “hot tumors” (immune-responsive).
2. Induction of Immunogenic Cell Death (ICD)
Ivermectin may trigger a form of cancer cell death that:
- Releases tumor antigens
- Activates dendritic cells
-
Enhances immune recognition
This is a key mechanism for improving checkpoint inhibitor effectiveness.
3. Inhibition of Cancer Growth Pathways
Studies have shown ivermectin may interfere with:
- PAK1 signaling pathway
- Wnt/β-catenin pathway
-
Mitochondrial function in tumor cells
These pathways are often associated with tumor survival and immune evasion.
4. Potential Synergy With Immunotherapy
In preclinical models, ivermectin combined with checkpoint inhibitors demonstrated:
- Greater tumor reduction
- Enhanced immune activation
- Improved response compared to either treatment alone
Trial Design: Treatment Protocol Explained
The study follows a structured 21-day treatment cycle, combining oral ivermectin with intravenous immunotherapy.
Treatment Schedule
| Component | Schedule | Notes |
|---|---|---|
| Ivermectin (oral) | Days 1–3, 8–10, 15–17 | Pulsed dosing within each cycle |
| Balstilimab (IV) | Day 1 | Anti-PD-1 checkpoint inhibitor |
| Pembrolizumab (IV) | Day 1 | Alternative treatment arm |
| Cycle Length | 21 days | Repeated up to 35 cycles (~2 years) |
Treatment Protocol variations complete Ivermectin dosage guide
- Disease progression
- Unacceptable toxicity
- Patient withdrawal
Patient Eligibility Criteria
To participate, patients must meet specific requirements:
Inclusion Criteria:
- Confirmed metastatic TNBC (ER-, PR-, HER2-)
- At least one prior line of systemic therapy
- Measurable disease (RECIST criteria)
- ECOG performance status 0–1
- Adequate liver, kidney, and bone marrow function
Exclusion Criteria:
- Severe prior immune-related adverse events
-
Certain uncontrolled medical conditions
Patients should consult ClinicalTrials.gov (NCT05318469) for full eligibility details and recruitment status.
Early Findings and Current Status
As of 2025–2026, the trial is ongoing, and no definitive conclusions have been published. However, early-stage observations suggest:
- The combination appears generally tolerable
- There are signals of immune activation
-
Some patients may experience clinical benefit
What This Trial Can and Cannot Prove
What It CAN Tell Us:
- Safety and tolerability of ivermectin with immunotherapy
- Dose-limiting toxicities
- Early tumor response rates (ORR, DCR)
- Pharmacokinetic interactions
What It CANNOT Prove (Yet):
- That ivermectin treats or cures TNBC
- Superiority over standard-of-care therapies
-
Long-term survival benefits
Large Phase III trials would be required for those conclusions.
Why This Research Matters
1. Expanding Immunotherapy Success
If ivermectin helps activate immune response, it could:
👉 Increase the number of patients who benefit from checkpoint inhibitors
2. Drug Repurposing Potential
Ivermectin has:
- Decades of human safety data (for approved uses)
-
Low cost and global availability
This makes it a strong candidate for repurposing in oncology.
3. Broader Oncology Applications
If successful, this strategy could extend beyond TNBC to:
- Lung cancer
- Melanoma
- Other solid tumors treated with immunotherapy
Scientific Context: Promise vs Evidence
While the science is compelling, it is critical to maintain a balanced perspective:
Strengths:
- Strong biological rationale
- Encouraging preclinical data
-
Early human investigation underway
Limitations:
- Lack of large-scale human evidence
- Unknown optimal dosing in cancer
- No confirmed survival benefit
Key Takeaways
- NCT05318469 is a Phase I/II trial testing ivermectin with immunotherapy in metastatic TNBC
- The study is based on preclinical evidence of immune modulation and tumor suppression
- Treatment involves pulsed oral ivermectin + IV checkpoint inhibitors
- The trial is focused on safety and early efficacy signals, not definitive outcomes
- Ivermectin is not approved for cancer treatment and remains investigational
Final Verdict: Can Ivermectin Enhance Immunotherapy?
The honest answer: It’s possible—but not yet proven.
This trial represents an important step in understanding whether a widely used drug like ivermectin can:
✔ Enhance immune response
✔ Improve checkpoint inhibitor outcomes
✔ Offer a new adjunct strategy in oncology
However, until larger, controlled trials are completed, ivermectin should be viewed strictly as an experimental approach within clinical research settings.
Protocol Stack (Quick Links)
Products related to fenbendazole mentioned in this article. Links are provided for convenience — always review the label and consult a professional before use.
All products are registered with FDA.
90 capsules — 99% purity, laboratory tested
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Ivermectin is not approved for the treatment of cancer. Patients should not self-prescribe and should consult a qualified oncologist before considering any treatment decisions or clinical trial participation.
